A. Schrag, Y. Ben-shlomo, and N. Quinn, Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study, The Lancet, vol.354, issue.9192, pp.1771-1776, 1999.
DOI : 10.1016/S0140-6736(99)04137-9

F. Tison, F. Yekhlef, V. Chrysostome, and C. Sourgen, Prevalence of multiple system atrophy, The Lancet, vol.355, issue.9202, pp.495-501, 2000.
DOI : 10.1016/S0140-6736(00)82050-4

G. Wenning, F. Geser, and F. Krismer, The natural history of multiple system atrophy: a prospective European cohort study, The Lancet Neurology, vol.12, issue.3, pp.264-74, 2013.
DOI : 10.1016/S1474-4422(12)70327-7

H. Watanabe, Y. Saito, and S. Terao, Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients, Brain, vol.125, issue.5, pp.1070-83, 2002.
DOI : 10.1093/brain/awf117

Y. Ben-shlomo, G. Wenning, F. Tison, and N. Quinn, Survival of patients with pathologically proven multiple system atrophy: A meta-analysis, Neurology, vol.48, issue.2, pp.384-93, 1997.
DOI : 10.1212/WNL.48.2.384

G. Wenning, B. Shlomo, Y. Magalhaes, M. Daniel, S. Quinn et al., Clinical features and natural history of multiple system atrophy, Brain, vol.117, issue.4, pp.835-880, 1994.
DOI : 10.1093/brain/117.4.835

A. Schrag, G. Wenning, N. Quinn, and Y. Ben-shlomo, Survival in multiple system atrophy, Movement Disorders, vol.76, issue.2, pp.294-300, 2008.
DOI : 10.1002/mds.21839

E. Krim, F. Yekhlef, V. Chrysostome, I. Ghorayeb, and F. Tison, Atrophie multisyst??matis??e : survie et facteurs pronostiques dans la cohorte ?? MSA-Aquitaine ??, Revue Neurologique, vol.163, issue.1, pp.54-65, 2007.
DOI : 10.1016/S0035-3787(07)90355-0

O. Sullivan, S. Massey, L. Williams, and D. , Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, vol.131, issue.5, pp.1362-72, 2008.
DOI : 10.1093/brain/awn065

M. Jecmenica-lukic, W. Poewe, E. Tolosa, and G. Wenning, Premotor signs and symptoms of multiple system atrophy, The Lancet Neurology, vol.11, issue.4, pp.361-369, 2012.
DOI : 10.1016/S1474-4422(12)70022-4

R. Sakakibara, T. Hattori, and T. Uchiyama, Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation?, Journal of Neurology, Neurosurgery & Psychiatry, vol.68, issue.1, pp.65-74, 2000.
DOI : 10.1136/jnnp.68.1.65

N. Damon-perriere, F. Tison, and W. Meissner, Multiple system atrophy, Psychologie & neuropsychiatrie du vieillissement, vol.8, issue.3, pp.179-91, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00732479

I. Yabe, H. Soma, A. Takei, N. Fujiki, T. Yanagihara et al., MSA-C is the predominant clinical phenotype of MSA in Japan: Analysis of 142 patients with probable MSA, Journal of the Neurological Sciences, vol.249, issue.2, pp.115-136, 2006.
DOI : 10.1016/j.jns.2006.05.064

I. Ghorayeb, B. Bioulac, and F. Tison, Sleep disorders in multiple system atrophy, Journal of Neural Transmission, vol.49, issue.Suppl 6, pp.1669-75, 2005.
DOI : 10.1007/s00702-005-0348-7

G. Plazzi, R. Corsini, and F. Provini, REM sleep behavior disorders in multiple system atrophy, Neurology, vol.48, issue.4, pp.1094-1101, 1997.
DOI : 10.1212/WNL.48.4.1094

N. Tachibana, K. Kimura, K. Kitajima, A. Shinde, J. Kimura et al., REM sleep motor dysfunction in multiple system atrophy: with special emphasis on sleep talk as its early clinical manifestation, Journal of Neurology, Neurosurgery & Psychiatry, vol.63, issue.5, pp.678-81, 1997.
DOI : 10.1136/jnnp.63.5.678

I. Stankovic, F. Krismer, and A. Jesic, Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group, Movement Disorders, vol.45, issue.Suppl 12, pp.857-67, 2014.
DOI : 10.1002/mds.25880

F. Tison, G. Wenning, M. Volonte, W. Poewe, P. Henry et al., Pain in multiple system atrophy, Journal of Neurology, vol.58, issue.2, pp.153-159, 1996.
DOI : 10.1007/BF02444007

M. Visser, J. Marinus, A. Stiggelbout, and J. Van-hilten, Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA-AUT, Movement Disorders, vol.32, issue.11, pp.1306-1318, 2004.
DOI : 10.1002/mds.20153

D. Sletten, G. Suarez, P. Low, J. Mandrekar, W. A. Singer et al., COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score Health-related quality of life in multiple system atrophy, Mayo Clinic proceedings Movement disorders : official journal of the Movement Disorder Society, vol.87, issue.216, pp.1196-201, 2006.

W. Meissner, A. Foubert-samier, and S. Dupouy, Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL), Revue Neurologique, vol.169, issue.1, pp.53-61, 2013.
DOI : 10.1016/j.neurol.2012.02.011

L. Massey, C. Micallef, and D. Paviour, Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy, Movement Disorders, vol.17, issue.Pt 12, pp.1754-62, 2012.
DOI : 10.1002/mds.24968

E. Kraft, J. Schwarz, C. Trenkwalder, T. Vogl, T. Pfluger et al., The Combination of Hypointense and Hyperintense Signal Changes on T2-Weighted Magnetic Resonance Imaging Sequences, Archives of Neurology, vol.56, issue.2, pp.225-233, 1999.
DOI : 10.1001/archneur.56.2.225

E. Kraft, C. Trenkwalder, and D. Auer, T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease, Neurology, vol.59, issue.8, pp.1265-1272, 2002.
DOI : 10.1212/01.WNL.0000032757.66992.3C

Y. Horimoto, I. Aiba, and T. Yasuda, Longitudinal MRI study of multiple system atrophy when do the findings appear, and what is the course [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy, Journal of neurology Movement disorders : official journal of the Movement Disorder Society, vol.249, issue.166, pp.847-54, 2001.

T. Eckert, A. Barnes, and V. Dhawan, FDG PET in the differential diagnosis of parkinsonian disorders, NeuroImage, vol.26, issue.3, pp.912-933, 2005.
DOI : 10.1016/j.neuroimage.2005.03.012

F. Tison, Les syndromes parkinsoniens atypiques et secondaires, 2006.

S. Gilman, G. Wenning, and P. Low, Second consensus statement on the diagnosis of multiple system atrophy, Neurology, vol.71, issue.9, pp.670-676, 2008.
DOI : 10.1212/01.wnl.0000324625.00404.15

G. Wenning and C. Colosimo, Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy, Revue Neurologique, vol.166, issue.10, pp.829-862, 2010.
DOI : 10.1016/j.neurol.2010.07.004

N. Quinn, Multiple system atrophy--the nature of the beast., Journal of Neurology, Neurosurgery & Psychiatry, vol.52, issue.Suppl, pp.78-87, 1989.
DOI : 10.1136/jnnp.52.Suppl.78

O. Flabeau, W. Meissner, and F. Tison, Multiple system atrophy: current and future approaches to management, Therapeutic Advances in Neurological Disorders, vol.3, issue.4, pp.249-63, 2010.
DOI : 10.1177/1756285610375328

R. Constantinescu, I. Richard, R. Kurlan, G. Wenning, F. Tison et al., Levodopa responsiveness in disorders with parkinsonism: a review of the literature 2141-8; quiz 295 Multiple system atrophy: a review of 203 pathologically proven cases, Movement disorders : official journal of the Movement Disorder Society Movement disorders : official journal of the Movement Disorder Society, vol.22, issue.122, pp.133-180, 1997.

S. Jain, J. Dawson, N. Quinn, and E. Playford, Occupational therapy in multiple system atrophy: A pilot randomized controlled trial, Movement Disorders, vol.44, issue.11, pp.1360-1364, 2004.
DOI : 10.1002/mds.20211

R. Freeman, Neurogenic Orthostatic Hypotension, New England Journal of Medicine, vol.358, issue.6, pp.615-639, 2008.
DOI : 10.1056/NEJMcp074189

K. Deguchi, K. Ikeda, and I. Sasaki, Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure, Journal of neurology Journal of neurology neurosurgery, and psychiatry, vol.254, issue.7512, pp.735-775, 2004.

R. Wright, H. Kaufmann, and R. Perera, A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension, Neurology, vol.51, issue.1, pp.120-124, 1998.
DOI : 10.1212/WNL.51.1.120

P. Low, J. Gilden, R. Freeman, K. Sheng, and M. Mcelligott, Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group, JAMA: The Journal of the American Medical Association, vol.277, issue.13, pp.1046-51, 1997.
DOI : 10.1001/jama.277.13.1046

J. Jankovic, J. Gilden, and B. Hiner, Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine, The American Journal of Medicine, vol.95, issue.1, pp.38-48, 1993.
DOI : 10.1016/0002-9343(93)90230-M

Z. Ahmed, Y. Asi, and A. Sailer, The neuropathology, pathophysiology and genetics of multiple system atrophy, Neuropathology and Applied Neurobiology, vol.64, issue.12, pp.4-24, 2012.
DOI : 10.1111/j.1365-2990.2011.01234.x

M. Papp, J. Kahn, and P. Lantos, Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome), Journal of the Neurological Sciences, vol.94, issue.1-3, pp.1-3, 1989.
DOI : 10.1016/0022-510X(89)90219-0

K. Wakabayashi, M. Yoshimoto, S. Tsuji, and H. Takahashi, Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy, Neuroscience letters, vol.249, pp.2-3, 1998.

M. Spillantini, M. Schmidt, V. Lee, J. Trojanowski, R. Jakes et al., Alpha-synuclein in Lewy bodies, Nature, vol.388, issue.6645, pp.839-879, 1997.
DOI : 10.1038/42166

M. Spillantini, R. Crowther, R. Jakes, M. Hasegawa, and M. Goedert, ??-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proceedings of the National Academy of Sciences, vol.95, issue.11, pp.6469-73, 1998.
DOI : 10.1073/pnas.95.11.6469

T. Ozawa, D. Paviour, and N. Quinn, The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations, Brain, vol.127, issue.12, pp.2657-71, 2004.
DOI : 10.1093/brain/awh303

T. Ozawa, Morphological substrate of autonomic failure and neurohormonal dysfunction in multiple system atrophy: impact on determining phenotype spectrum, Acta Neuropathologica, vol.43, issue.Pt 4, pp.201-212, 2007.
DOI : 10.1007/s00401-007-0254-1

Y. Song, D. Lundvig, and Y. Huang, p25?? Relocalizes in Oligodendroglia from Myelin to Cytoplasmic Inclusions in Multiple System Atrophy, The American Journal of Pathology, vol.171, issue.4, pp.1291-303, 2007.
DOI : 10.2353/ajpath.2007.070201

A. Matsuo, I. Akiguchi, G. Lee, E. Mcgeer, P. Mcgeer et al., Myelin Degeneration in Multiple System Atrophy Detected by Unique Antibodies, The American Journal of Pathology, vol.153, issue.3, pp.735-779, 1998.
DOI : 10.1016/S0002-9440(10)65617-9

J. Duda, B. Giasson, and T. Gur, Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of ??-Synuclein Permutations in Multiple System Atrophy, Journal of Neuropathology & Experimental Neurology, vol.59, issue.9, pp.830-871, 2000.
DOI : 10.1093/jnen/59.9.830

M. Spillantini, R. Crowther, R. Jakes, N. Cairns, P. Lantos et al., Filamentous ??-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neuroscience Letters, vol.251, issue.3, pp.205-213, 1998.
DOI : 10.1016/S0304-3940(98)00504-7

K. Jellinger and P. Lantos, Papp???Lantos inclusions and the pathogenesis of multiple system atrophy: an update, Acta Neuropathologica, vol.60, issue.Suppl 1, pp.657-67, 2010.
DOI : 10.1007/s00401-010-0672-3

M. Papp and P. Lantos, The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology, Brain, vol.117, issue.2, pp.235-278, 1994.
DOI : 10.1093/brain/117.2.235

M. Inoue, S. Yagishita, M. Ryo, K. Hasegawa, N. Amano et al., The distribution and dynamic density of oligodendroglial cytoplasmic inclusions (GCIs) in multiple system atrophy: a correlation between the density of GCIs and the degree of involvement of striatonigral and olivopontocerebellar systems, Acta Neuropathologica, vol.93, issue.6, pp.585-91, 1997.
DOI : 10.1007/s004010050655

M. Papp and P. Lantos, Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy, Journal of the Neurological Sciences, vol.107, issue.2, pp.172-82, 1992.
DOI : 10.1016/0022-510X(92)90286-T

S. Kato and H. Nakamura, Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies, Acta Neuropathologica, vol.80, issue.6, pp.584-94, 1990.
DOI : 10.1007/BF00294235

H. Lashuel, C. Overk, A. Oueslati, and E. Masliah, The many faces of ??-synuclein: from structure and toxicity to therapeutic target, Nature Reviews Neuroscience, vol.418, issue.1, pp.38-48, 2013.
DOI : 10.1038/nrn3406

I. Murray, Synucleinopathies: a pathological and molecular review, Clinical Neuroscience Research, vol.1, issue.6, pp.445-55, 2001.
DOI : 10.1016/S1566-2772(01)00023-8

F. Lee, F. Liu, Z. Pristupa, and H. Niznik, Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis, The FASEB Journal, vol.15, issue.6, pp.916-942, 2001.
DOI : 10.1096/fj.00-0334com

O. Marques, Alpha-synuclein: from secretion to dysfunction and death, Cell Death and Disease, vol.46, issue.7, 2012.
DOI : 10.1038/cddis.2012.94

S. Scholz, H. Houlden, and C. Schulte, variants are associated with increased risk for multiple system atrophy, Annals of Neurology, vol.13, issue.5, pp.610-614, 2009.
DOI : 10.1002/ana.21685

K. Vekrellis, M. Xilouri, E. Emmanouilidou, H. Rideout, and L. Stefanis, Pathological roles of ??-synuclein in neurological disorders, The Lancet Neurology, vol.10, issue.11, pp.1015-1040, 2011.
DOI : 10.1016/S1474-4422(11)70213-7

D. Miller, J. Johnson, S. Solano, Z. Hollingsworth, D. Standaert et al., Absence of ??-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia, Journal of Neural Transmission, vol.45, issue.[Suppl 12], pp.1613-1637, 2005.
DOI : 10.1007/s00702-005-0378-1

J. Reyes, N. Rey, L. Bousset, R. Melki, P. Brundin et al., Alpha-synuclein transfers from neurons to oligodendrocytes, Glia, vol.22, issue.Pt 1, pp.387-98, 2014.
DOI : 10.1002/glia.22611

URL : https://hal.archives-ouvertes.fr/hal-01181201

Y. Asi, J. Simpson, and P. Heath, Alpha-synuclein mRNA expression in oligodendrocytes in MSA, Glia, vol.208, issue.7, pp.964-70, 2014.
DOI : 10.1002/glia.22653

J. Souza, B. Giasson, Q. Chen, V. Lee, and H. Ischiropoulos, Dityrosine Cross-linking Promotes Formation of Stable alpha -Synuclein Polymers. IMPLICATION OF NITRATIVE AND OXIDATIVE STRESS IN THE PATHOGENESIS OF NEURODEGENERATIVE SYNUCLEINOPATHIES, Journal of Biological Chemistry, vol.275, issue.24, pp.18344-18353, 2000.
DOI : 10.1074/jbc.M000206200

V. Uversky, J. Li, and A. Fink, Evidence for a Partially Folded Intermediate in alpha -Synuclein Fibril Formation, Journal of Biological Chemistry, vol.276, issue.14, pp.10737-10781, 2001.
DOI : 10.1074/jbc.M010907200

L. Serpell, J. Berriman, R. Jakes, M. Goedert, and R. Crowther, Fiber diffraction of synthetic alpha -synuclein filaments shows amyloid-like cross-beta conformation, Proceedings of the National Academy of Sciences, vol.97, issue.9, pp.4897-902, 2000.
DOI : 10.1073/pnas.97.9.4897

B. Giasson, I. Murray, J. Trojanowski, and V. Lee, A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of ??-Synuclein Is Essential for Filament Assembly, Journal of Biological Chemistry, vol.276, issue.4, pp.2380-2386, 2001.
DOI : 10.1074/jbc.M008919200

O. Marques and T. Outeiro, Alpha-synuclein: from secretion to dysfunction and death, Cell Death and Disease, vol.46, issue.7, p.350, 2012.
DOI : 10.1038/cddis.2012.94

B. Winner, R. Jappelli, and S. Maji, In vivo demonstration that ??-synuclein oligomers are toxic, Proceedings of the National Academy of Sciences, vol.108, issue.10, pp.4194-4203, 2011.
DOI : 10.1073/pnas.1100976108

H. Braak, U. Rub, W. Gai, D. Tredici, and K. , Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen, Journal of Neural Transmission, vol.110, issue.5, pp.517-553, 2003.
DOI : 10.1007/s00702-002-0808-2

H. Braak, D. Tredici, K. Rub, U. De-vos, R. et al., Staging of brain pathology related to sporadic Parkinson???s disease, Neurobiology of Aging, vol.24, issue.2, pp.197-211, 2003.
DOI : 10.1016/S0197-4580(02)00065-9

E. Angot, J. Steiner, C. Hansen, J. Li, and P. Brundin, Are synucleinopathies prion-like disorders?, The Lancet Neurology, vol.9, issue.11, pp.1128-1166, 2010.
DOI : 10.1016/S1474-4422(10)70213-1

C. Hawkes, D. Tredici, K. Braak, and H. , Parkinson's disease: a dual-hit hypothesis, Neuropathology and Applied Neurobiology, vol.70, issue.6, pp.599-614, 2007.
DOI : 10.1007/s007050050016

C. Hawkes, D. Tredici, K. Braak, and H. , Parkinson's Disease, Annals of the New York Academy of Sciences, vol.67, issue.Suppl 1, pp.615-637, 2009.
DOI : 10.1111/j.1749-6632.2009.04365.x

H. Lee, S. Patel, and S. Lee, Intravesicular Localization and Exocytosis of ??-Synuclein and its Aggregates, Journal of Neuroscience, vol.25, issue.25, pp.6016-6040, 2005.
DOI : 10.1523/JNEUROSCI.0692-05.2005

O. El-agnaf, S. Salem, and K. Paleologou, Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma al. Detection of oligomeric forms of alphasynuclein protein in human plasma as a potential biomarker for Parkinson's disease, FASEB journal : official publication of the Federation of American Societies for Experimental Biology El-Agnaf OM FASEB journal : official publication of the Federation of American Societies for Experimental Biology, vol.17, issue.203, pp.1945-1952, 2003.

W. Gai, J. Power, P. Blumbergs, J. Culvenor, and P. Jensen, Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components, Journal of neurochemistry, vol.73, issue.5, pp.2093-100, 1999.

G. Kovacs, L. Laszlo, and J. Kovacs, Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies, Neurobiology of Disease, vol.17, issue.2, pp.155-62, 2004.
DOI : 10.1016/j.nbd.2004.06.006

J. Ovadi, F. Orosz, A. Lehotzky, P. Lau, N. Tokesi et al., Tubulin polymerizationpromoting protein (TPPP/p25) is critical for oligodendrocyte differentiation Role of TPPP/p25 on alpha-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy, Kragh CL, Lund LB, Febbraro F, et al. Alpha-synuclein aggregation and Ser-129, pp.676-86, 2009.

N. Stefanova, M. Reindl, M. Neumann, P. Kahle, W. Poewe et al., Microglial activation mediates neurodegeneration related to oligodendroglial ??-synucleinopathy: Implications for multiple system atrophy, Movement Disorders, vol.28, issue.15, pp.2196-203, 2007.
DOI : 10.1002/mds.21671

N. Stefanova, F. Tison, M. Reindl, W. Poewe, G. Wenning et al., Animal models of multiple system atrophy, Trends in Neurosciences, vol.28, issue.9, pp.501-507, 2005.
DOI : 10.1016/j.tins.2005.07.002

E. Hirsch, S. Hunot, and A. Hartmann, Neuroinflammatory processes in Parkinson's disease, Parkinsonism & Related Disorders, vol.11
DOI : 10.1016/j.parkreldis.2004.10.013

C. Shults, E. Rockenstein, and L. Crews, Neurological and Neurodegenerative Alterations in a Transgenic Mouse Model Expressing Human ??-Synuclein under Oligodendrocyte Promoter: Implications for Multiple System Atrophy, Journal of Neuroscience, vol.25, issue.46, pp.10689-99, 2005.
DOI : 10.1523/JNEUROSCI.3527-05.2005

J. Duda, B. Giasson, and Q. Chen, Widespread Nitration of Pathological Inclusions in Neurodegenerative Synucleinopathies, The American Journal of Pathology, vol.157, issue.5, pp.1439-1484, 2000.
DOI : 10.1016/S0002-9440(10)64781-5

P. Fernagut, B. Dehay, and A. Maillard, Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies, Neurobiology of Disease, vol.67, pp.133-142, 2014.
DOI : 10.1016/j.nbd.2014.03.021

URL : https://hal.archives-ouvertes.fr/hal-01217333

G. Bensimon, A. Ludolph, and Y. Agid, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study, Brain, vol.132, issue.1, pp.156-71, 2009.
DOI : 10.1093/brain/awn291

URL : https://hal.archives-ouvertes.fr/hal-00603311

J. Trojanowski and J. Growdon, A New Consensus Report on Biomarkers for the Early Antemortem Diagnosis of Alzheimer Disease: Current Status, Relevance to Drug Discovery, and Recommendations for Future Research, Journal of Neuropathology & Experimental Neurology, vol.57, issue.6, pp.643-647, 1998.
DOI : 10.1097/00005072-199806000-00010

M. Jakowec, G. Petzinger, S. Sastry, D. Donaldson, A. Mccormack et al., The native form of ??-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls, Neuroscience Letters, vol.253, issue.1, pp.13-19, 1998.
DOI : 10.1016/S0304-3940(98)00599-0

B. Mollenhauer, J. Locascio, W. Schulz-schaeffer, F. Sixel-doring, C. Trenkwalder et al., ??-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, The Lancet Neurology, vol.10, issue.3, pp.230-270, 2011.
DOI : 10.1016/S1474-4422(11)70014-X

S. Hall, A. Ohrfelt, and R. Constantinescu, Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders, Archives of Neurology, vol.69, issue.11, pp.1445-52, 2012.
DOI : 10.1001/archneurol.2012.1654

F. Tateno, R. Sakakibara, T. Kawai, M. Kishi, and T. Murano, Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease, Alzheimer Disease & Associated Disorders, vol.26, issue.3, pp.213-219, 2012.
DOI : 10.1097/WAD.0b013e31823899cc

Y. Wang, M. Shi, and K. Chung, Phosphorylated alpha-synuclein in Parkinson's disease, Science translational medicine, vol.4, issue.121, pp.121-141, 2012.

M. Shi, J. Bradner, and A. Hancock, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Annals of Neurology, vol.9, issue.25, pp.570-80, 2011.
DOI : 10.1002/ana.22311

S. Mondello, R. Constantinescu, H. Zetterberg, U. Andreasson, B. Holmberg et al., CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders, Parkinsonism & related disorders, 2014.

M. Aerts, R. Esselink, W. Abdo, B. Bloem, and M. Verbeek, CSF alpha-synuclein does not differentiate between parkinsonian disorders, Neurobiology of aging, vol.33, issue.2, pp.430-431, 2012.
DOI : 10.1016/j.neurobiolaging.2010.12.001

URL : http://doi.org/10.1016/j.neurobiolaging.2010.12.001

M. Herbert, J. Eeftens, and M. Aerts, CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls, Parkinsonism & Related Disorders, vol.20, issue.1, pp.112-117, 2014.
DOI : 10.1016/j.parkreldis.2013.09.003

S. Slaets, E. Vanmechelen, L. Bastard, and N. , Increased CSF alpha-synuclein levels in Alzheimer's disease: Correlation with tau levels Alzheimer's & dementia : the journal of the Alzheimer's Association 2014: Epub ahead of print

P. Foulds, O. Yokota, and A. Thurston, Post mortem cerebrospinal fluid ??-synuclein levels are raised in multiple system atrophy and distinguish this from the other ??-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies, Neurobiology of Disease, vol.45, issue.1, pp.188-95, 2012.
DOI : 10.1016/j.nbd.2011.08.003

B. Mollenhauer, E. Trautmann, and B. Otte, ??-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system, Journal of Neural Transmission, vol.119, issue.301, pp.739-785, 2012.
DOI : 10.1007/s00702-012-0784-0

R. Barbour, K. Kling, and J. Anderson, Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood, Neurodegenerative Diseases, vol.5, issue.2, pp.55-64, 2008.
DOI : 10.1159/000112832

P. Lee, G. Lee, H. Park, O. Bang, I. Joo et al., The plasma alpha-synuclein levels in patients with Parkinson???s disease and multiple system atrophy, Journal of Neural Transmission, vol.55, issue.10, pp.1435-1444, 2006.
DOI : 10.1007/s00702-005-0427-9

Z. Sun, X. Xiang, and Z. Chen, Increase of the plasma ??-synuclein levels in patients with multiple system atrophy, Movement Disorders, vol.105, issue.1-2, pp.375-384, 2014.
DOI : 10.1002/mds.25688

W. Van-geel, W. Abdo, R. Melis, S. Williams, B. Bloem et al., A more efficient enzyme-linked immunosorbent assay for measurement of ??-synuclein in cerebrospinal fluid, Journal of Neuroscience Methods, vol.168, issue.1, pp.182-187, 2008.
DOI : 10.1016/j.jneumeth.2007.09.021

R. Tinsley, K. Kotschet, and D. Modesto, Sensitive and specific detection of alpha-synuclein in human plasma, Journal of neuroscience research, vol.88, issue.12, pp.2693-700, 2010.

B. Mollenhauer, V. Cullen, and I. Kahn, Direct quantification of CSF ??-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Experimental Neurology, vol.213, issue.2, pp.315-340, 2008.
DOI : 10.1016/j.expneurol.2008.06.004

B. Mollenhauer, Quantification of ??-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson's disease?, Parkinsonism & Related Disorders, vol.20, issue.1, pp.76-85, 2014.
DOI : 10.1016/S1353-8020(13)70020-8

K. Brannstrom, M. Lindhagen-persson, and A. Gharibyan, A Generic Method for Design of Oligomer-Specific Antibodies, PLoS ONE, vol.267, issue.1, p.90857, 2014.
DOI : 10.1371/journal.pone.0090857.s003

M. Bidinosti, D. Shimshek, and B. Mollenhauer, Novel One-step Immunoassays to Quantify ??-Synuclein: APPLICATIONS FOR BIOMARKER DEVELOPMENT AND HIGH-THROUGHPUT SCREENING, Journal of Biological Chemistry, vol.287, issue.40, pp.33691-705, 2012.
DOI : 10.1074/jbc.M112.379792

Y. Compta, L. Parkkinen, O. Sullivan, and S. , Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, vol.134, issue.5, pp.1493-505, 2011.
DOI : 10.1093/brain/awr031

M. Kalaitzakis, A. Walls, R. Pearce, and S. Gentleman, Striatal A?? peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes, Neurobiology of Disease, vol.41, issue.2, pp.377-84, 2011.
DOI : 10.1016/j.nbd.2010.10.005

J. Olah, O. Vincze, and D. Virok, Interactions of Pathological Hallmark Proteins: TUBULIN POLYMERIZATION PROMOTING PROTEIN/p25, ??-AMYLOID, AND ??-SYNUCLEIN, Journal of Biological Chemistry, vol.286, issue.39, pp.34088-100, 2011.
DOI : 10.1074/jbc.M111.243907

B. Holmberg, B. Johnels, K. Blennow, and L. Rosengren, Cerebrospinal fluid A?42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy, Movement Disorders, vol.125, issue.2, pp.186-90, 2003.
DOI : 10.1002/mds.10321

B. Mollenhauer, M. Bibl, and H. Esselmann, Tauopathies and synucleinopathies: Do cerebrospinal fluid ??-amyloid peptides reflect disease-specific pathogenesis?, Journal of Neural Transmission, vol.54, issue.Suppl 12, pp.919-946, 2007.
DOI : 10.1007/s00702-007-0629-4

S. Sussmuth, I. Uttner, and B. Landwehrmeyer, Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes, Movement Disorders, vol.312, issue.Pt 6, pp.1284-1292, 2010.
DOI : 10.1002/mds.22895

S. Bech, L. Hjermind, and L. Salvesen, Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes, Parkinsonism & Related Disorders, vol.18, issue.1, pp.69-72, 2012.
DOI : 10.1016/j.parkreldis.2011.08.012

M. Verbeek, W. Abdo, D. Jong, D. Horstink, M. Kremer et al., levels in multiple system atrophy, Movement Disorders, vol.40, issue.2, pp.238-278, 2004.
DOI : 10.1002/mds.10687

S. Jesse, J. Brettschneider, and S. Sussmuth, Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases, Journal of Neurology, vol.14, issue.2, pp.1034-1075, 2011.
DOI : 10.1007/s00415-010-5876-x

R. Constantinescu, U. Andreasson, and S. Li, Proteomic profiling of cerebrospinal fluid in parkinsonian disorders, Parkinsonism & Related Disorders, vol.16, issue.8, pp.545-554, 2010.
DOI : 10.1016/j.parkreldis.2010.06.011

L. Salvesen, S. Bech, and A. Lokkegaard, The DJ-1 concentration in cerebrospinal fluid does not differentiate among parkinsonian syndromes, Parkinsonism & Related Disorders, vol.18, issue.7, pp.899-901, 2012.
DOI : 10.1016/j.parkreldis.2012.03.013

H. Drexler and H. Quentmeier, Mini ReviewFLT3: Receptor and Ligand, Growth Factors, vol.22, issue.2, pp.71-74, 2004.
DOI : 10.1080/08977190410001700989

S. Chua, R. Bielecki, C. Wong, N. Yamanaka, I. Rogers et al., Neural progenitors, neurons and oligodendrocytes from human umbilical cord blood cells in a serum-free, feeder-free cell culture, Biochemical and Biophysical Research Communications, vol.379, issue.2, pp.217-238, 2009.
DOI : 10.1016/j.bbrc.2008.12.045

C. Brazel, M. Ducceschi, B. Pytowski, and S. Levison, The FLT3 Tyrosine Kinase Receptor Inhibits Neural Stem/Progenitor Cell Proliferation and Collaborates with NGF to Promote Neuronal Survival, Molecular and Cellular Neuroscience, vol.18, issue.4, pp.381-93, 2001.
DOI : 10.1006/mcne.2001.1033

E. Silajdzic, R. Constantinescu, B. Holmberg, M. Bjorkqvist, and O. Hansson, Flt3 ligand does not differentiate between Parkinsonian disorders, Movement disorders : official journal of the Movement Disorder Society, vol.2014

B. Olsson, R. Constantinescu, B. Holmberg, N. Andreasen, K. Blennow et al., The glial marker YKL-40 is decreased in synucleinopathies, Movement Disorders, vol.23, issue.13, pp.1882-1887, 2013.
DOI : 10.1002/mds.25589

W. Abdo, D. Jong, D. Hendriks, and J. , Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease, Movement Disorders, vol.13, issue.5, pp.571-580, 2004.
DOI : 10.1002/mds.10714

B. Holmberg, L. Rosengren, J. Karlsson, and B. Johnels, Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease, Movement Disorders, vol.37, issue.1, pp.70-77, 1998.
DOI : 10.1002/mds.870130116

R. Constantinescu, L. Rosengren, B. Johnels, H. Zetterberg, and B. Holmberg, Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical parkinsonian disorders, Parkinsonism & Related Disorders, vol.16, issue.2, pp.142-147, 2010.
DOI : 10.1016/j.parkreldis.2009.07.007

Y. Wang, A. Hancock, and J. Bradner, Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy, The American Journal of Pathology, vol.178, issue.4, pp.1509-1525, 2011.
DOI : 10.1016/j.ajpath.2011.01.006

E. Kaufman, S. Hall, Y. Surova, H. Widner, O. Hansson et al., Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy, PLoS ONE, vol.21, issue.4, p.62354, 2013.
DOI : 10.1371/journal.pone.0062354.t002

C. Konings, M. Kuiper, T. Teerlink, C. Mulder, P. Scheltens et al., Normal cerebrospinal fluid glutathione concentrations in Parkinson???s disease, Alzheimer???s disease and multiple system atrophy, Journal of the Neurological Sciences, vol.168, issue.2, pp.112-117, 1999.
DOI : 10.1016/S0022-510X(99)00167-7

A. Kikuchi, A. Takeda, and H. Onodera, Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson's Disease and Multiple System Atrophy, Neurobiology of Disease, vol.9, issue.2, pp.244-252, 2002.
DOI : 10.1006/nbdi.2002.0466

N. Ishigami, T. Tokuda, and M. Ikegawa, Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy, Movement Disorders, vol.79, issue.Suppl, pp.851-858, 2012.
DOI : 10.1002/mds.24994

L. Taupenot, K. Harper, O. Connor, and D. , The Chromogranin???Secretogranin Family, New England Journal of Medicine, vol.348, issue.12, pp.1134-1183, 2003.
DOI : 10.1056/NEJMra021405

K. Helle, Regulatory peptides from chromogranin A and secretogranin II: Putative modulators of cells and tissues involved in inflammatory conditions, Regulatory Peptides, vol.165, issue.1, pp.45-51, 2010.
DOI : 10.1016/j.regpep.2009.09.009

K. Helle, The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects, Biological Reviews, vol.266, issue.4, pp.769-94, 2004.
DOI : 10.1016/S0167-4838(97)00137-4

M. Chen, P. Tempst, and B. Yankner, Secretogranin I/Chromogranin B Is a Heparin-Binding Adhesive Protein, Journal of Neurochemistry, vol.250, issue.5, pp.1691-1699, 1992.
DOI : 10.1016/0003-9861(83)90149-2

M. Paik, Y. Ahn, and P. Lee, Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy, Clinica Chimica Acta, vol.411, issue.19-20, pp.19-20, 2010.
DOI : 10.1016/j.cca.2010.05.034

P. Lee, G. Lee, and M. Paik, Polyunsaturated fatty acid levels in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy, Movement Disorders, vol.277, issue.2, pp.309-319, 2008.
DOI : 10.1002/mds.21846

A. Vallelunga, M. Ragusa, D. Mauro, and S. , Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy, Frontiers in Cellular Neuroscience, vol.8, p.156, 2014.
DOI : 10.3389/fncel.2014.00156

W. Abdo, B. Bloem, V. Geel, W. Esselink, R. Verbeek et al., CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease, Neurobiology of Aging, vol.28, issue.5, pp.742-749, 2007.
DOI : 10.1016/j.neurobiolaging.2006.03.010

W. Abdo, B. Van-de-warrenburg, H. Kremer, B. Bloem, and M. Verbeek, CSF biomarker profiles do not differentiate between the cerebellar and parkinsonian phenotypes of multiple system atrophy, Parkinsonism & Related Disorders, vol.13, issue.8, pp.480-482, 2007.
DOI : 10.1016/j.parkreldis.2007.02.002

B. Holmberg, B. Johnels, P. Ingvarsson, B. Eriksson, and L. Rosengren, CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes, Parkinsonism & Related Disorders, vol.8, issue.1, pp.23-31, 2001.
DOI : 10.1016/S1353-8020(00)00083-3

A. Petzold, E. Thompson, and G. Keir, Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy, Journal of the Neurological Sciences, vol.279, issue.1-2, pp.76-85, 2009.
DOI : 10.1016/j.jns.2008.12.037

J. Brettschneider, A. Petzold, and S. Sussmuth, Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes, Movement Disorders, vol.225, issue.12, pp.2224-2231, 2006.
DOI : 10.1002/mds.21124

J. Martinez-rodriguez, K. Seppi, and A. Cardozo, Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy, Movement Disorders, vol.184, issue.12, pp.1822-1826, 2007.
DOI : 10.1002/mds.21668

W. Abdo, B. Bloem, H. Kremer, G. Lammers, M. Verbeek et al., CSF hypocretin-1 levels are normal in multiple-system atrophy, Parkinsonism & Related Disorders, vol.14, issue.4, pp.342-346, 2008.
DOI : 10.1016/j.parkreldis.2007.08.012

R. Polinsky, R. Brown, R. Burns, J. Harvey-white, and I. Kopin, Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.7, pp.914-923, 1988.
DOI : 10.1136/jnnp.51.7.914

D. Goldstein, C. Holmes, and O. Bentho, Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy, Parkinsonism & Related Disorders, vol.14, issue.8, pp.600-607, 2008.
DOI : 10.1016/j.parkreldis.2008.01.010

D. Goldstein, C. Holmes, and Y. Sharabi, Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies, Brain, vol.135, issue.6, pp.1900-1913, 2012.
DOI : 10.1093/brain/aws055

D. Goldstein, C. Holmes, N. Patronas, and I. Kopin, Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension, Clinical Science, vol.104, issue.6, pp.649-54, 2003.
DOI : 10.1042/CS20020315

D. Goldstein, C. Holmes, Y. Sharabi, S. Brentzel, and G. Eisenhofer, Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension, Neurology, vol.60, issue.8, pp.1327-1359, 2003.
DOI : 10.1212/01.WNL.0000058766.46428.F3

N. Ichikawa, Study on monoamine metabolite contents of cerebrospinal fluid in patients with neurodegenerative diseases., The Tohoku Journal of Experimental Medicine, vol.150, issue.4, pp.435-481, 1986.
DOI : 10.1620/tjem.150.435

K. Nishi, T. Kondo, H. Narabayashi, H. Takubo, S. Muramoto et al., Unresponsiveness to l-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid, Journal of the Neurological Sciences, vol.92, issue.1, pp.65-70, 1989.
DOI : 10.1016/0022-510X(89)90175-5

D. Goldstein, R. Polinsky, and M. Garty, Patterns of plasma levels of catechols in neurogenic orthostatic hypotension, Annals of Neurology, vol.245, issue.4, pp.558-63, 1989.
DOI : 10.1002/ana.410260410

B. Lindvall and J. Olsson, Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia, Advances in neurology, vol.53, pp.117-139, 1990.

E. Martignoni, F. Blandini, F. Petraglia, C. Pacchetti, G. Bono et al., Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type Journal of neural transmission Parkinson's disease and dementia section, pp.191-205, 1992.

M. Kuiper, C. Konings, P. Bergmans, and E. Wolters, Whole blood monoamine oxidase activity in Parkinson's disease and multiple system atrophy patients, Journal of the Neurological Sciences, vol.117, issue.1-2, pp.41-46, 1993.
DOI : 10.1016/0022-510X(93)90152-O

H. Kuroda, Gamma-aminobutyric acid (GABA) in cerebrospinal fluid, Acta medica Okayama, vol.37, issue.3, pp.167-77, 1983.

P. Tosca, L. Canevari, D. Paolo, and E. , Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy, Acta Neurologica Scandinavica, vol.12, issue.6, pp.430-435, 1992.
DOI : 10.1111/j.1600-0404.1992.tb06042.x

R. Polinsky, K. Holmes, R. Brown, and V. Weise, CSF acetylcholinesterase levels are reduced in multiple system atrophy with autonomic failure, Neurology, vol.39, issue.1, pp.40-44, 1989.
DOI : 10.1212/WNL.39.1.40

M. Konagaya, Y. Konagaya, and M. Iida, CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems, Rinsho shinkeigaku = Clinical neurology, vol.32, issue.3, pp.266-71, 1992.

A. Williams, R. Levine, T. Chase, W. Lovenberg, and D. Calne, CFS hydroxylase cofactor levels in some neurological diseases., Journal of Neurology, Neurosurgery & Psychiatry, vol.43, issue.8, pp.735-743, 1980.
DOI : 10.1136/jnnp.43.8.735

R. Duvoisin, W. Nicklas, V. Ritchie, J. Sage, and S. Chokroverty, Low leukocyte glutamate dehydrogenase activity does not correlate with a particular type of multiple system atrophy., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.12, pp.1508-1519, 1988.
DOI : 10.1136/jnnp.51.12.1508

S. Sorbi, S. Tonini, E. Giannini, S. Piacentini, P. Marini et al., Abnormal platelet glutamate dehydrogenase activity and activation in dominant and nondominant olivopontocerebellar atrophy, Annals of Neurology, vol.7, issue.3, pp.239-284, 1986.
DOI : 10.1002/ana.410190304

Y. Konagaya, M. Konagaya, and T. Takayanagi, Glutamate dehydrogenase and its isozyme activity in olivopontocerebellar atrophy, Journal of the Neurological Sciences, vol.74, issue.2-3, pp.231-237, 1986.
DOI : 10.1016/0022-510X(86)90108-5

G. Finocchiaro, F. Taroni, D. Donato, and S. , Glutamate dehydrogenase in olivopontocerebellar atrophies: leukocytes, fibroblasts, and muscle mitochondria, Neurology, vol.36, issue.4, pp.550-553, 1986.
DOI : 10.1212/WNL.36.4.550

D. Aubby, H. Saggu, P. Jenner, N. Quinn, A. Harding et al., Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders., Journal of Neurology, Neurosurgery & Psychiatry, vol.51, issue.7, pp.893-902, 1988.
DOI : 10.1136/jnnp.51.7.893

M. Kuiper, C. Mulder, G. Van-kamp, P. Scheltens, and E. Wolters, Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy, Journal of Neural Transmission - Parkinson's Disease and Dementia Section, vol.50, issue.2, pp.109-123, 1994.
DOI : 10.1007/BF02260965

M. Kuiper, T. Teerlink, J. Visser, P. Bergmans, P. Scheltens et al., L-Glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients, Journal of Neural Transmission, vol.107, issue.2, pp.183-192, 2000.
DOI : 10.1007/s007020050016

T. Tokuda, M. Qureshi, and M. Ardah, Detection of elevated levels of ??-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, vol.75, issue.20, pp.1766-72, 2010.
DOI : 10.1212/WNL.0b013e3181fd613b

Z. Hong, M. Shi, and K. Chung, DJ-1 and ??-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, vol.133, issue.3, pp.713-739, 2010.
DOI : 10.1093/brain/awq008

J. Kang, D. Irwin, and A. Chen-plotkin, Association of cerebrospinal fluid beta-amyloid 1- 42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease, JAMA neurology, vol.70, issue.10, pp.1277-87, 2013.

W. Meissner, A. Foubert-samier, and S. Dupouy, Assessment of quality of life with the multiple system atrophy health-related quality of life scale, Movement Disorders, vol.21, issue.12, pp.1574-1581, 2012.
DOI : 10.1002/mds.25174

A. Hughes, S. Daniel, Y. Ben-shlomo, and A. Lees, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain, vol.125, issue.4, pp.861-70, 2002.
DOI : 10.1093/brain/awf080

A. Fagan, C. Roe, C. Xiong, M. Mintun, J. Morris et al., Cerebrospinal Fluid tau/??-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults, Archives of Neurology, vol.64, issue.3, pp.343-352, 2007.
DOI : 10.1001/archneur.64.3.noc60123

L. Shaw, H. Vanderstichele, and M. Knapik-czajka, Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Annals of Neurology, vol.55, issue.4, pp.403-416, 2009.
DOI : 10.1002/ana.21610

G. Wenning, F. Tison, and K. Seppi, Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS), Movement Disorders, vol.60, issue.12, pp.1391-402, 2004.
DOI : 10.1002/mds.20255